Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, and despite recent advancements, most patients die of their disease. Although immune checkpoint blockade became part of the standard-of-care for patients with metastatic G/GEJ cancers, its efficacy and impact on the tumor...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Nature medicine Ročník 30; číslo 2; s. 519 - 530
Hlavní autori:	Verschoor, Yara L., van de Haar, Joris, van den Berg, José G., van Sandick, Johanna W., Kodach, Liudmila L., van Dieren, Jolanda M., Balduzzi, Sara, Grootscholten, Cecile, IJsselsteijn, Marieke E., Veenhof, Alexander A. F. A., Hartemink, Koen J., Vollebergh, Marieke A., Jurdi, Adham, Sharma, Shruti, Spickard, Erik, Owers, Emilia C., Bartels-Rutten, Annemarieke, den Hartog, Peggy, de Miranda, Noel F. C. C., van Leerdam, Monique E., Haanen, John B. A. G., Schumacher, Ton N., Voest, Emile E., Chalabi, Myriam
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	New York Nature Publishing Group US 01.02.2024 Nature Publishing Group
Predmet:	631/67/580 692/308/2779/109/1941 692/308/53 692/699/67/1504/1829 Adenocarcinoma Adenocarcinoma - drug therapy Adenocarcinoma - pathology Adverse events Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Apoptosis Biomedical and Life Sciences Biomedicine Cancer Cancer Research CD8 antigen Cell death Chemotherapy Effectiveness Esophageal Neoplasms Esophagogastric Junction - pathology Fatalities Humans Immune checkpoint inhibitors Immunotherapy Infectious Diseases Lymphocytes Lymphocytes T Medical prognosis Metabolic Diseases Metastases Molecular Medicine Monoclonal antibodies Neoadjuvant Therapy Neurosciences Oxaliplatin Patients PD-1 protein PD-L1 protein Programmed Cell Death 1 Receptor Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology Targeted cancer therapy Tumor Microenvironment Tumors
ISSN:	1078-8956, 1546-170X, 1546-170X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!